Biosion
Latest round
- Series B
Last raised
- Apr 2023
Total raised
- $19M
Investors
- 7
About Biosion
Established in 2017 and based in Nanjing, China, Biosion, Inc. is a biotechnology company that engages in the research and development and production of antibody drugs for tumors and immune diseases. Dr. Mingjiu Chen, the company's founder, used to work as a senior scientist at AbbVie. It has oversea offices in the US and Australia. The company engages in the research and development and production of antibody drugs for immune and oncologic diseases. It self-developed the H3 antibody discovery platform, SynAb collaborative antibody discovery platform, and SynTracer antibody endocytosis screening platform. The H3 antibody discovery platform provides high-throughput, high-capacity screening services for drug molecules. It developed mono and bi-specific protein therapeutics, antibody-drug conjugates, and macrophage reprogramming agents for oncology and immunology. Its main product, BSI-045B (anti-TSLP mAb), is in phase II for severe asthma and phase-I for atopic dermatitis. n August 2025, Biosion, Inc.
Who invested in Biosion
7 investors across 3 rounds
See all investors in Biosion
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Biosion
Who invested in Biosion?
Biosion has 7 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Biosion raised?
Biosion has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Biosion last raise money?
Biosion's most recent round on record is a Series B, in Apr 2023.
What does Biosion do?
Established in 2017 and based in Nanjing, China, Biosion, Inc.
Where is Biosion headquartered?
Biosion is headquartered in Nanjing, China.
Which VCs invest in companies like Biosion?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Biosion's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Biosion? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.